https://doi.org/10.1016/S1473-3099(21)00170-5 Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study
(14 april 2021). Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nature Medicine. DOI: 10.1038/s41591-021-01318-5.
(23 maart 2021). Model-based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant. DOI: 10.1101/2021.03.03.21252706. Geraadpleegd op 9 april 2021. “Table 1: Summary of the fitted parameters and respective confidence intervals considering the entire period, November 1 2020-January 31, 2021 maintaining the same pathogenicity of the previous variant. Parameter: Relative transmission rate for the new variant. Estimate: 2.52. 2.50%: 2.27. 97.50%: 2.78.”.
(April 2021). Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees. medRxiv. DOI: 10.1101/2021.04.23.441101.
(23 maart 2021). Model-based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant. DOI: 10.1101/2021.03.03.21252706. Geraadpleegd op 9 april 2021. “Table 1: Summary of the fitted parameters and respective confidence intervals considering the entire period, November 1 2020-January 31, 2021 maintaining the same pathogenicity of the previous variant. Parameter: Relative transmission rate for the new variant. Estimate: 2.52. 2.50%: 2.27. 97.50%: 2.78.”.
